All Photos(1)

Documents

1279000

USP

Fluorouracil

Name: Fluorouracil
Brand: USP

United States Pharmacopeia (USP) Reference Standard

Sign Into View Organizational & Contract Pricing

All Photos(1)

Synonym(s):

5-Fluorouracil, 2,4-Dihydroxy-5-fluoropyrimidine, 5-FU, 5-Fluoro-2,4(1H,3H)-pyrimidinedione

Empirical Formula (Hill Notation):

C₄H₃FN₂O₂

CAS Number:

51-21-8

Molecular Weight:

130.08

Beilstein:

127172

MDL number:

MFCD00006018

PubChem Substance ID:

329749871

grade

pharmaceutical primary standard

API family

fluorouracil

manufacturer/tradename

USP

mp

282-286 °C (dec.) (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

FC1=CNC(=O)NC1=O

InChI

1S/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9)

InChI key

GHASVSINZRGABV-UHFFFAOYSA-N

Gene Information

human ... TYMS(7298)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Analytical Reference Standards

Pharmacopeia & Metrological Institute Standards

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Fluorouracil USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.

Other Notes

Sales restrictions may apply.

related product

Product No.

Description

Pricing

1279054

1279065

1279019

1279021

BP995

Fluorouracil, British Pharmacopoeia (BP) Reference Standard

PHR2584

5,6-Diamino-1,3-dimethyluracil, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2865

PHR2866

PHR2867

PHR2868

Pictograms

GHS06,GHS08

Signal Word

Danger

Hazard Statements

H301 - H351

Precautionary Statements

P202 - P264 - P280 - P301 + P310 - P405 - P501

Hazard Classifications

Acute Tox. 3 Oral - Carc. 2

Storage Class Code

6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Documents related to the products that you have purchased in the past have been gathered in the Document Library for your convenience.

Visit the Document Library

Difficulty Finding Your Product Or Lot/Batch Number?

How to Find the Product Number

Product numbers are combined with Pack Sizes/Quantity when displayed on the website (example: T1503-25G). Please make sure you enter ONLY the product number in the Product Number field (example: T1503).

Example:

T1503

Product Number

25G

Pack Size/Quantity

Additional examples:

705578-5MG-PW

PL860-CGA/SHF-1EA

MMYOMAG-74K-13

1000309185

enter as 1.000309185)

Having trouble? Feel free to contact Technical Service for assistance.

How to Find a Lot/Batch Number for COA

Lot and Batch Numbers can be found on a product's label following the words 'Lot' or 'Batch'.

Aldrich Products

For a lot number such as TO09019TO, enter it as 09019TO (without the first two letters 'TO').
For a lot number with a filling-code such as 05427ES-021, enter it as 05427ES (without the filling-code '-021').
For a lot number with a filling-code such as STBB0728K9, enter it as STBB0728 without the filling-code 'K9'.

Not Finding What You Are Looking For?

In some cases, a COA may not be available online. If your search was unable to find the COA you can request one.

Request COA

Thymidine phosphorylase is both a therapeutic and a suicide gene in a murine model of mitochondrial neurogastrointestinal encephalomyopathy.

S López-Estévez et al.

Gene therapy, 21(7), 673-681 (2014-05-09)

Suicide gene therapy (SGT) is a promising strategy for treating cancer. In this work, we show that thymidine phosphorylase (TP) deficiency, the underlying genetic defect in mitochondrial neurogastrointestinal encephalomyopathy (MNGIE), presents an opportunity to apply SGT using capecitabine, a commonly

Role of miR-200 family members in survival of colorectal cancer patients treated with fluoropyrimidines.

Tania Diaz et al.

Journal of surgical oncology, 109(7), 676-683 (2014-02-11)

Surgery is the standard treatment for colorectal cancer (CRC), and adjuvant chemotherapy has been shown to be effective in stage III but less so in stage II. We have analyzed the expression of the miR-200 family in tissue samples from

Comparison of survival of patients with BCLC stage A hepatocellular carcinoma after hepatic resection or transarterial chemoembolization: a propensity score-based analysis.

Zhe Guo et al.

Annals of surgical oncology, 21(9), 3069-3076 (2014-04-15)

It is unclear whether hepatic resection (HR) or transarterial chemoembolization (TACE) is associated with better outcomes for patients with hepatocellular carcinoma (HCC) in Barcelona Clinic Liver Cancer (BCLC) stage A. The present study compared survival for patients with BCLC stage

Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy.

John M L Ebos et al.

EMBO molecular medicine, 6(12), 1561-1576 (2014-11-02)

Thousands of cancer patients are currently in clinical trials evaluating antiangiogenic therapy in the neoadjuvant setting, which is the treatment of localized primary tumors prior to surgical intervention. The rationale is that shrinking a tumor will improve surgical outcomes and

Navigating later lines of treatment for advanced colorectal cancer - optimizing targeted biological therapies to improve outcomes.

Sharlene Gill et al.

Cancer treatment reviews, 40(10), 1171-1181 (2014-12-03)

Colorectal cancer (CRC) is the third most commonly diagnosed cancer among males and second among females worldwide. The treatment landscape for advanced CRC (aCRC) is rapidly evolving and there are now a number of randomized trials assessing treatment of aCRC

View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service